Chemotherapy for advanced pancreatic cancer in older patients (literature review)
https://doi.org/10.17650/2686-9594-2022-12-3-51-55
Abstract
Elderly patients with malignant neoplasms of the pancreas are poorly represented in large clinical trials. Thus, in the MPACT and ACCORD study, the median age of patients with malignant neoplasms of the pancreas was 61 years, and it remains unclear whether the results obtained can be extrapolated to older patients, whom we most often encounter in real clinical practice. The vast majority of studies that analyzed the efficacy and tolerability of systemic chemotherapy in elderly and senile patients showed good tolerability of gemcitabine monotherapy, the tolerability of combined chemotherapy regimens among older patients with pancreatic adenocarcinoma varied between studies, but was expectedly higher than with monotherapy. with regard to survival rates, the effectiveness of systemic chemotherapy has also been shown here, especially combined regimens among elderly patients. But almost all studies were retrospective or included a small number of patients, which does not allow assessing the reliability of the results. The question of the advisability of intensifying chemotherapy in elderly and senile patients remains open.
About the Authors
M. Sh. Manukyan
N. N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
Маriam Shirakovna Manukyan
24 Kashirskoe Shosse, Moscow 115478
I. S. Bazin
N. N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
A. A. Tryakin
N. N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
References
1. Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49. DOI: 10.3322/caac.21660
2. SEER Stat Fact Sheets: pancreatic cancer. Available at: http://seer.cancer.gov/statfacts/html/pancreas.html.
3. Wang H., Liu J., Xia G. et al. Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study. Sci Rep 2020;10:7048. DOI: 10.1038/s41598-020-64068-3
4. Smith B.D., Smith G.L., Hurria A. et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758–65.
5. Conroy T., Desseigne F., Ychou M. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817–25. DOI: 10.1056/NEJMoa1011923
6. Vogel A., Römmler-Zehrer J., Li J.S. et al. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer 2016;16(1):817. DOI: 10.1186/s12885-016-2798-8
7. Peixoto R.D., Ho M., Renouf D.J. et al. Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nabpaclitaxel plus gemcitabine versus FOLFIRINOX. Am J Clin Oncol 2017;40(5):507–11. DOI: 10.1097/COC.0000000000000193
8. Kuroda T., Kumagi T., Yokota T. et al. Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients. BMC Gastroenterol 2017;17(1):66. DOI: 10.1186/s12876-017-0623-8
9. Gourgou-Bourgade S., Bascoul-Mollevi C., Desseigne F. еt al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013;31(1):23–9. DOI: 10.1200/JCO.2012.44.4869
10. Guion-Dusserre J.-F., Bertaut A., Ghiringhelli F. еt al. Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy. World J Gastroenterol 2016;22(42):9378–86. DOI: 10.3748/wjg.v22.i42.9378
11. Mizrahi J.D., Rogers J.E., Hess K.R. et al. Modified FOLFIRINOX in pancreatic cancer patients age 75 or older. Pancreatology 2020;20(3):501–4. DOI: 10.1016/j.pan.2020.01.005
12. Manukyan M., Bazin I., Tryakin A., Rays A. P-224 Тoxicity and tolerability of the mFOLFIRINOX regimen in young elderly and older elderly patients with pancreatic carcinoma (PC). Ann Oncol 2022;33(4 Suppl):S328. DOI: 10.1016/j.annonc.2022.04.314
13. Petrillo A., Pappalardo A., Calabrese F. et al. First line nabpaclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age. J Gastrointest Oncol 2019;10(5):910–7. DOI: 10.21037/jgo.2019.06.02
14. Vivaldi C., Salani F., Rovesti G. et al. First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? Eur J Cancer 2020;137: 108–16. DOI: 10.1016/j.ejca.2020.06.031
15. Han S.Y., Kim D.U., Seol Y.M. et al. First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy. World J Clin Cases 2020;8(18):4022–33. DOI: 10.12998/wjcc.v8.i18.4022
Review
Views:
284
Email this article 